Camilo Caceres Galvis

Md. | Internal Medicine @UdeA | Oncologist at Clínica Universitaria Colombia

[Camilo Caceres Galvis @caceres_258]

En esencia es la misma fuente, pero vista desde otra perspectiva.
Primer día de internado (izq) y último día de residencia (der). @sanvicentefund

[Stephen V Liu, MD @StephenVLiu]

Dr. Chad Rusthoven at #WCLC26 presents results from SWOG S1827, the phase III MAVERICK study exploring the benefit of PCI in pts with SCLC. Historic studies before the era of MRI surveillance showed a decrease in brain metastases with PCI and an improvement in OS but recent ES-SCLC studies called the OS improvement into question. MAVERICK looks at both LS and ES disease - note primary endpoint here is cognitive failure free survival (time to cognitive failure or death) with OS as a key secondary.

[Alfredo Addeo MD @Alfdoc2]

The randomized phase III trial evaluating time-of-day in NSCLC has been retracted due to major concerns regarding trial registration, protocol inconsistencies, and data integrity.https://t.co/CxaOoXlbGg
This should not discourage researchers working on chronotherapy. The question remains important,but it deserves answers generated through rigorous, transparent, and reproducible science. @PTarantinoMD @Timothee_MD

[Yüksel Ürün @DrYukselUrun]

This is not simply a new pancreatic cancer drug.

It is a reminder that even “undruggable” biology can become treatable with persistence.

Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

[Uğur Özkerim @UOzkerim]

One of the most striking thoracic abstracts heading into #ASCO26: LORIN✨✅

Neoadjuvant lorlatinib achieved:

• pCR: 46.9% 🔥🔥
• MPR: 81.3%
• 75% conversion-to-surgery in initially unresectable stage III ALK+ NSCLC

ALK-positive early-stage disease may become the next frontier of precision oncology. @OncoAlert @brunolarvol @OncBrothers @OncoReporte @MedwatchKate @weoncologists @LungCancerEu @ASCO

@bmassutis @UmbertoMalapel1
@jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo
@Latinamd @JulienMazieres @TerriConneran @BRicciutiMD

[Dr Amol Akhade @SuyogCancer]

Does time of immunotherapy infusion matters ?
No . Opposite results from asco 2025 presentation. Looking forward to full presentation.
LBA2 iTIMES @myESMO #ELCC2026 @Tony_Calles @Alfdoc2 @BalazsHalmosMD @FordePatrick @OncoAlert

[Stephen V Liu, MD @StephenVLiu]

Clear survival gains in treating lung cancer reflected in this @NEJM article. All pts with lung cancer treated in public hospitals in France show median survival improved from 8.5 months in 2000 to 20.7 months in 2020. No room for nihilism anymore!

https://t.co/dElSAUW0ep

[Ilana Schlam @IlanaSchlam]

Wrapping up another fantastic #SABCS!

Amazing, practice-changing data were presented.

I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!

#SABCS24 @OncoAlert

[M.Provencio @MARIANOPROVENCI]

With #NADIM at @gecp_org, we were disruptive. We had to overcome skepticism to break the standard.
Today, 5years later, @TheLancetOncol confirms the robustness of our strategy.
69% alive at 5Y, without severe toxicities.
Congratulations
📌https://t.co/agtSUoqpQ1

[Stephen V Liu, MD @StephenVLiu]

Cardiotoxicity of osimertinib in real world population with #EGFR NSCLC @JTOonline. In 1126 pts, incidence of osimertinib-related cardiac dysfunction was 4.7% (3.4% required some intervention). Recovery rate was 82.4% (similar if discontinued or not).

https://t.co/t41aDXmvmN

[Camilo Caceres Galvis @caceres_258]

@FabioTorressav @graham74GC @TheIACH @Mohty_EBMT @UsuarezMD @jcalvarezpa

[Dr Amol Akhade @SuyogCancer]

So Those with NO PCR post neoadjuvant IO or those with PD-L1 low ( less than 1% ) , adjuvant IO may be more useful.

We will never have Head to head trials of Neo adjuvant vs adjuvant vs Perioperative IO in NSCLC.

So probably in these subgroups, one should consider adjuvant IO after neo adjuvant IO in NSCLC.
Great 👍 analysis by @FordePatrick @IASLC @PatelOncology @Alfdoc2 @JackWestMD @DrJNaidoo #WCLC2024

[Stephen V Liu, MD @StephenVLiu]

Overview of outcomes with 1L osimertinib @JTOonline. At progression, continuation of osimertinib associated with shorter survival compared to those who discontinued (!), even after multivariate analysis and even among those who began chemotherapy.

https://t.co/fewJ1YzBZa

[Marcelo Corassa, MD. @MarceloCorassa]

LAURA shows impressive PFS improvement, with 39.1 mo for Osi x 5.6 mo for placebo, HR 0.16. The main question remains: we will just be amazed by HRs and p values or we will deeply discuss that some of our patients will be on Osimertinib forever? #ASCO24

[Yakup Ergün @dr_yakupergun]

#ASCO24 Plenary Session

ADRIATIC: Durvalumab as consolidation tx for pts with limited-stage SCLC

Durva vs PBO
OS➡️56 vs 33.4 mo
PFS➡️16.6 vs 9.2 mo
G3/4 pneumonitis➡️3.0 vs 2.6%

💥An advancement in LC-SCLC after many years, and it is definitely practice-changing

@OncoAlert

[Paolo Tarantino @PTarantinoMD]

Press release: the addition of pembro to neoadjuvant chemo improves OS in stage II-III TNBC.

Tremendous news for one of the greatest unmet needs in breast oncology.

Next step: tailoring strategies to preserve the benefit while minimizing IO-toxicities.

https://t.co/anMdAVbPvI

[Rafael Parra-Medina @rafa_p10]

Posición de post-doctorado @INCancerologia

[JAMA Oncology @JAMAOnc]

The 10-year interval between colonoscopy screenings for colorectal cancer (CRC) could be extended to 15 years in patients with no family history of CRC and negative findings on their first colonoscopy, finds matched cohort study. https://t.co/EAHso7RyYx

[Dr. Iván R. González @Dr_Ivanoncologo]

The NEOpredict-Lung study represents an important🤓evolution in the treatment of resectable NSCLC🫁, evaluating the feasibility and safety of preoperative combined treatment of nivolumab and relatlimab. The selection of this therapeutic approach was based on the premise that co-modulation of PD-1 and LAG-3-mediated immune pathways could enhance antitumor responses and improve clinical outcomes in patients with stage IB, II, and IIIA NSCLC.
🎯With a cohort of 60 treatment-naïve patients with no biomarker selection, this randomized phase 2 trial demonstrated the feasibility of surgery in all cases, with a curative resection rate of 95%.
🎯Pathologic and radiographic findings underscore the efficacy of this combination, with pathologic responses observed in 27% of patients treated with nivolumab and 30% of those receiving nivolumab and relatlimab. The impressive pathologically complete resection rate of 100% in the nivolumab group and 90% in the nivolumab and relatlimab group corroborates the efficacy of these treatments in completely removing the tumor and affected lymph nodes.
🎯In addition, the results at 12 months show a disease-free survival of 89% and an overall survival of 93% in the nivolumab group, while in the nivolumab and relatlimab group, even more encouraging rates of 93% and 100% were recorded, respectively. Importantly, the safety of both therapies was acceptable, with grade ≥3 adverse events reported in 10% and 13% of patients, suggesting a favorable tolerability profile.
🎯These results are consistent with the potential clinical and biological benefit of dual inhibition of PD-1 and LAG-3 pathways, suggesting a promising new therapeutic strategy to improve outcomes in this NSCLC patient population. @OncoAlert @LungCancerFaces @lcfamerica @Lungsolutions @lara_pijuan @oncologician
https://t.co/Qmt4HM6NaT

[Raul Pinilla @rapinilla]

Simposio Tumores Gastrointestinales ACHO!

[OncoAlert @OncoAlert]

Just out at @ESMO_Open
by our @OncoAlert 🚨colleagues @JordiRemon, @barlesi and team

(INNOVATED) Immune checkpoint blockers in solid organ transplant recipients and cancer

Evaluating the efficacy and safety of immune checkpoint blockers in solid organ transplant patients w/solid tumors, particularly #LungCancer 🫁

➡️revealing promising response rates but also highlighting significant risks of allograft rejection.

https://t.co/y2eg62XXsI

@dplanchard @BenjaminBesseMD @GautschiOliver @delvysra

Pinging @OncoALert 🚨 #LungCancer Faculty
@ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @JackWestMD @bmassutis @Tony_Calles @s_couraud @marinagarassino @peters_solange @UmbertoMalapel1 @g_mountzios @CharuAggarwalMD @christine_lovly @BairdAM @JFreemanDaily @Piuchagarrido @LeciaSequist @jillfeldman4 @ivybelkins @bensolomon1 @VanitaNoronha @DrSanjayPopat @alexdrilon @DrJNaidoo @Latinamd

#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @dr_yakupergun @to_be_elizabeth